phrykt

Tenax Therapeutics, Inc. (TENX): who owns it and who trades it

As of Nov 16, 2026, TENX insiders reported 27 purchases worth $6.6M in the last 12 months. The largest buyer was Daniel Schneeberger (10% owner), with $3.2M. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Tenax Therapeutics

From the latest filings

Overall: more buying than selling. Funds, insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns TENX

111 funds and institutions reported TENX shares worth $442M at the end of Q2 2026, about 67% of the company. The largest holder is FMR LLC (Fidelity) with 8.7%.

Funds and institutions (13F) 67%Everyone else 33%

10 largest owners, by share of the company

FMR LLC (Fidelity)8.7%
Vivo Capital, LLC5.5%
BlackRock, Inc.3.8%
Perceptive Advisors LLC3.7%
Vanguard Capital Management LLC2.5%
Millennium Management LLC1.9%
Ikarian Capital, LLC1.7%
Candriam S.C.A.1.6%
Citadel Advisors LLC1.6%
Rtw Investments, LP1.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)3.94M8.66%$57.4M+1122%
Vivo Capital, LLC2.50M5.49%$36.4M+1100%
BlackRock, Inc.1.73M3.79%$25.1M+10078%
Perceptive Advisors LLC1.70M3.73%$24.7M+17%
Vanguard Capital Management LLC1.15M2.52%$16.7M+335%
Millennium Management LLC876,2301.92%$12.7M+64%
Ikarian Capital, LLC787,6001.73%$11.5M-23%
Candriam S.C.A.749,5881.65%$10.9MNew
Citadel Advisors LLC728,5611.60%$10.6M+378%
Rtw Investments, LP696,5701.53%$10.1M+88%
Stonepine Capital Management, LLC660,0001.45%$9.6M-32%
Geode Capital Management, LLC639,5371.40%$9.3M+825%
T. Rowe Price Associates607,6601.33%$8.8M-79%
Marshall Wace, LLP585,5781.29%$8.5M+66%
Braidwell LP584,4121.28%$8.5MNew
Point72 Asset Management, L.P.556,7611.22%$8.1M+4%
Velan Capital Investment Management LP549,9851.21%$8M-6%
Adage Capital Partners Gp, L.l.c.540,1261.19%$7.9MNo change
Woodline Partners LP531,2541.17%$7.7M+64%
State Street Corp510,8141.12%$7.4M+1662%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, TENX insiders reported $6.6M of open-market purchases and $0 of sales.

Purchases, 12 months
$6.6M
27 trades, 8 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Oct 21, 2026
Filed Oct 21, 2026

Purchases and sales by month

$2.5M$2.5MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 21, 2026ADAR1 Capital Management, LLC +110% ownerPurchase331,979$1.66$551KForm 4
Oct 20, 2026ADAR1 Capital Management, LLC +110% ownerPurchase254,342$1.60$406KForm 4
Oct 19, 2026ADAR1 Capital Management, LLC +110% ownerPurchase336,528$1.51$507KForm 4
Sep 16, 2026Declan DooganDirectorPurchase53,000$1.92$102KForm 4
Sep 15, 2026Christopher Thomas GiordanoCEOPurchase4,850$1.82$8.8KForm 4
Sep 11, 2026Christopher Thomas GiordanoCEOPurchase6,000$1.88$11.3KForm 4
Sep 11, 2026Thomas R Staab IICFOPurchase5,675$1.94$11KForm 4
Sep 3, 2026ADAR1 Capital Management, LLC +110% ownerPurchase900,000$1.78$1.6MForm 4
Sep 2, 2026Daniel Schneeberger +110% ownerPurchase187,704$1.80$338KForm 4
Sep 1, 2026Daniel Schneeberger +110% ownerPurchase179,058$1.80$322KForm 4
Aug 31, 2026Daniel Schneeberger +110% ownerPurchase403,571$1.79$722KForm 4
Aug 24, 2026Daniel Schneeberger +110% ownerPurchase107,374$1.75$188KForm 4
Aug 21, 2026Daniel Schneeberger +110% ownerPurchase716,369$1.77$1.3MForm 4
Aug 20, 2026Daniel Schneeberger +110% ownerPurchase202,124$1.78$360KForm 4
Dec 9, 2025Stuart RichDirectorPurchase2,500$10.22$25.6KForm 4
Dec 8, 2025Stuart RichDirectorPurchase2,500$10.10$25.2KForm 4
Dec 4, 2025Stuart RichDirectorPurchase2,500$9.20$23KForm 4
Dec 3, 2025Stuart RichDirectorPurchase1,500$9.08$13.6KForm 4
Dec 2, 2025Stuart RichDirectorPurchase1,000$9.01$9KForm 4
Nov 20, 2025Christopher Thomas GiordanoCEOPurchase538$7.59$4.1KForm 4
Nov 19, 2025Christopher Thomas GiordanoCEOPurchase455$7.51$3.4KForm 4
Nov 18, 2025Christopher Thomas GiordanoCEOPurchase1,612$7.75$12.5KForm 4
Nov 18, 2025June Sherie AlmenoffDirectorPurchase1,900$7.52$14.3KForm 4
Nov 17, 2025June Sherie AlmenoffDirectorPurchase93$7.15$665Form 4
Nov 17, 2025Thomas McgauleyCFOPurchase5,000$7.23$36.1KForm 4
Nov 17, 2025Thomas McgauleyCFOPurchase1,000$7.35$7.3KForm 4
Nov 17, 2025Thomas McgauleyCFOPurchase2,000$7.34$14.7KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Daniel Schneeberger10% owner$3.2M–Sep 2, 2026
ADAR1 Capital Management, LLC10% owner$3.1M–Oct 21, 2026
Declan DooganDirector$102K–Sep 16, 2026
Stuart RichChief Medical Officer, Director$96.4K–Dec 9, 2025
Thomas McgauleyInterim CFO$58.2K–Nov 17, 2025
Christopher Thomas GiordanoCEO, Director$40.1K–Sep 15, 2026
June Sherie AlmenoffDirector$15K–Nov 18, 2025
Thomas R Staab IIChief Financial Officer$11K–Sep 11, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

TENX short interest

High short interest. 15.5% of TENX shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 650%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 5.82M TENX shares were sold short, 15.5% of the shares outstanding, down 19.5% from the report before. At the average daily volume of 1.83M shares, buying them all back would take about 3.2 trading days (days to cover).

Shares short, % of all shares

15.5%May 15Oct 3027.8%

Days to cover

3.2May 15Oct 303.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20265.82M15.54%-20%1.83M3.2
Oct 15, 20267.23M19.32%+1%2.25M3.2
Sep 30, 20267.18M19.19%+30%3.06M2.4
Sep 15, 20265.50M14.71%-41%5.35M1.0
Aug 31, 20269.28M24.79%+69%8.25M1.1
Aug 14, 20265.47M14.63%+114%13.36M1.0
Jul 31, 20262.56M6.83%+25%1.37M1.9
Jul 15, 20262.05M11.90%+14%1.49M1.4
Jun 30, 20261.79M10.40%+133%1.51M1.2
Jun 15, 2026767,5324.46%-3%941,2121.0
May 29, 2026792,0414.61%+2%443,3191.8
May 15, 2026775,8514.51%+6%693,4641.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Tenax Therapeutics company events

Tenax Therapeutics filed 14 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Oct 8, 2026AnnouncementAs previously announced, Tenax Therapeutics, Inc. is enriching its LEVEL-2 clinical trial based on key learnings from its recently completed Phase 3 LEVEL trial of TNX-103 in PH-HFpEF. The Company intends to amend LEVEL-2 enrollment criteria, as set forth in the attached Investor Presentation. Filing
  3. Sep 9, 2026AnnouncementShared information with investors. Filing
  4. Aug 10, 2026AnnouncementTenax Therapeutics, Inc. issued a press release announcing topline results from its Phase 3 LEVEL clinical trial of TNX-103 in patients with PH-HFpEF. As announced, the Company intends to host a conference call and live webcast at 8:00 a.m., ET on August 10, 2026 related to those results. Filing
  5. Jul 31, 2026ResultsReleased financial results. Filing
  6. Jul 2, 2026AnnouncementTenax Therapeutics, Inc. issued a press release announcing that it will present results from its Phase 3 LEVEL clinical trial in a Late-Breaking Clinical Science session at the European Society of Cardiology (ESC) Congress 2026. Filing
  7. Jun 30, 2026AgreementSupply Agreement As previously disclosed, pursuant to the License Agreement (as defined below) between Tenax Therapeutics, Inc. and Orion Corporation, a Finnish corporation, Orion has the right to be the Company’s primary supplier of orally administered levosimendan product for development purposes… Filing
  8. Jun 29, 2026LeadershipThe Board of Directors of Tenax Therapeutics, Inc., upon the recommendation of the Compensation Committee of the Board, approved amendments to the employment agreements of Christopher Giordano, Thomas Staab, and Stuart Rich. Filing
  9. Jun 4, 2026VoteReported shareholder vote results. Filing
  10. May 12, 2026ResultsReleased financial results. Filing
  11. Apr 22, 2026LeadershipTenax Therapeutics, Inc. announced the appointment of Thomas R. Staab, II as Chief Financial Officer of the Company effective May 11, 2026. Filing
  12. Mar 10, 2026ResultsReleased financial results. Filing
  13. Jan 9, 2026LeadershipThe Company and its Chief Medical Officer, Dr. Stuart Rich, entered into a second amendment to Dr. Rich’s Executive Employment Agreement dated January 15, 2021, as amended on June 12, 2024. Filing
  14. Dec 17, 2025AnnouncementTenax Therapeutics, Inc. issued a press release announcing that the prespecified Blinded Sample Size Re-estimation (BSSR) of LEVEL, an ongoing, registrational Phase 3 clinical trial evaluating TNX-103 (oral levosimendan) in patients with pulmonary hypertension in heart failure with preserved… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Tenax Therapeutics financials

Famous investors that hold TENX

1 of the 50 well-known investors we track reported holding TENX in their latest 13F filing. The largest position is Israel Englander's, worth $2.6M.

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20261.36M$2.6M0.0%+56%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 20 filings named TENX in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Sirenia Capital Management LP13G5.4%
Nov 16, 2026Sirenia Capital Management LP13G5.4%
Nov 16, 2026ADAR1 Capital Management, LLC13G/A16.4%
Nov 16, 2026BIOTECHNOLOGY VALUE FUND L P13G/A8.2%
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G/A0.0%
Nov 16, 2026RTW Investments, LP13G/A0.0%
Nov 16, 2026Vestal Point Capital, LP13G/A0.0%
Nov 16, 2026BIOTECHNOLOGY VALUE FUND L P13G/A8.2%
Nov 16, 2026ADAR1 Capital Management, LLC13G/A16.4%
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G/A0.0%
Nov 16, 2026RTW Investments, LP13G/A0.0%
Nov 16, 2026Vestal Point Capital, LP13G/A0.0%
Nov 12, 2026Adage Capital Management, L.P.13G/A2.3%
Nov 12, 2026Adage Capital Management, L.P.13G/A2.3%
Oct 27, 2026BlackRock, Inc.13G/A7.5%
Oct 27, 2026BlackRock, Inc.13G/A7.5%
Oct 15, 2026Millennium Management LLC13G/A3.6%
Oct 15, 2026Millennium Management LLC13G/A3.6%
Oct 13, 2026Sphera Funds Management Ltd.13G/A7.1%
Oct 13, 2026Sphera Funds Management Ltd.13G/A7.1%

Questions about Tenax Therapeutics, Inc. (TENX) stock

Who owns the most TENX stock?

The largest reported owner of Tenax Therapeutics, Inc. (TENX) is FMR LLC (Fidelity), with 8.7% of the company. In total, 111 funds and institutions reported holding TENX at the end of Q2 2026, together about 67% of the shares. See the largest owners.

Are TENX insiders buying or selling?

In the last 12 months, TENX insiders reported 27 open-market purchases worth $6.6M and no sales. The latest trade was on Oct 21, 2026. See every trade.

What is the short interest in TENX?

As of Oct 30, 2026, 5.82M TENX shares were sold short, 15.5% of the shares outstanding, down 19.5% from the report before. At the average daily volume of 1.83M shares, buying them all back would take about 3.2 trading days (days to cover). See the history.

Which famous investors hold TENX?

1 of the 50 well-known investors we track reported TENX in their latest 13F filing, including Israel Englander. The largest position is worth $2.6M. See all holders.

Executive pay

Tenax Therapeutics's chief executive was paid a total of $8.1M for the year ended Dec 31, 2025, up 9% from $7.4M the year before. In the last 12 months, Tenax Therapeutics's executives and directors bought $322K of stock on the open market and sold none.

Chief executive, total pay$8.1MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$21.7MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.9MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.